20 Aug Felicyn for Feline HCM: Now Available, But Is It Right for Your Cat?
Felicyn for Feline HCM marks a new chapter in feline cardiology. Hypertrophic cardiomyopathy (HCM) remains the most common heart disease in cats, causing thickening of the heart muscle that makes it harder for the heart to relax and fill properly. Some cats remain stable for years, while others progress quickly, developing congestive heart failure, blood clots, or even sudden death. For decades, treatment options focused mainly on managing complications, with no therapy that could change the course of the disease itself—until now.
Felicyn for Feline HCM Is Here
Felicyn (Felycin-CA1), a delayed-release oral formulation of sirolimus (rapamycin), received conditional FDA approval in March 2025 for the management of ventricular hypertrophy in cats with subclinical HCM (Stage B disease). As of now, Felicyn is commercially available, marking the first FDA-approved drug for feline HCM. This is an important milestone in feline cardiology and represents the first therapeutic option aimed at modifying the disease process rather than only managing its complications.
What We Know So Far
The approval of Felicyn for Feline HCM is based on early clinical research, but there are still many unanswered questions. Here’s what veterinarians and cat owners should know at this stage:
- Clinical trial evidence: The RAPACAT trial showed that cats treated with sirolimus experienced a modest yet measurable reduction in heart muscle thickness compared to placebo.
- Clinical significance: While the effect was modest, experts consider it meaningful in the context of feline HCM, where treatment options have been limited.
- Short-term safety: At the approved dosing, Felicyn appeared safe with no evidence of immunosuppression.
- What remains unknown: It is still unclear whether Felicyn improves long-term survival, delays the onset of congestive heart failure, or enhances quality of life.
- Need for more data: Additional research will be essential to fully understand the long-term role of Felicyn in managing feline HCM.
Is Felicyn for Feline HCM Right for Every Cat?
While Felicyn represents an exciting new option, it is not appropriate for all cats with heart disease. It is currently approved only for cats with subclinical HCM (structural heart changes without clinical signs). It is not recommended for cats with congestive heart failure, diabetes, significant liver disease, or certain drug interactions.
Even within the approved patient population, treatment decisions must be individualized. Careful evaluation by a veterinary cardiologist is essential to determine whether Felicyn is the right choice for a particular cat. Baseline screening, including liver function assessment, is required before starting treatment.
Moving Forward
For families of cats with HCM, the availability of Felicyn represents hope and progress. However, it is not a cure, and it should not be started without a thorough discussion of risks, benefits, and unknowns. Every cat is different, and treatment recommendations remain tailored to disease stage, progression, and overall health. Felicyn may prove to be a valuable tool in slowing this disease in carefully selected patients, but for now, its role is one piece of a broader, individualized management plan.
Cat Cardiology Services in Nevada
For families of cats with HCM, the availability of Felicyn for Feline HCM represents hope and progress. However, it is not a cure, and it should not be started without a thorough discussion of risks, benefits, and unknowns. Every cat is different, and treatment recommendations remain tailored to disease stage, progression, and overall health. Felicyn may prove to be a valuable tool in slowing this disease in carefully selected patients, but for now, its role is one piece of a broader, individualized management plan.
If your cat has been diagnosed with HCM, we encourage you to contact us at Animal Cardiology Specialists of Nevada today to discuss whether Felicyn may be the right option for your cat.
Images used under creative commons license – commercial use (08/20/2025) Photo by Manja Vitolic on Unsplash